| Bioactivity | TP-024 (FTBMT) is a selective GPR52 agonist with an EC50 of 75 nM[1]. TP-024 has antipsychotic and procognitive properties[2]. |
| Target | IC50: 75 nM (GPR52) |
| Invitro | TP-024 (FTBMT) (0.1-10 μM) increases intracellular cAMP levels in CHO cells expressing human, mouse, or rat GPR52, with pEC50s of 7.03, 6.85, and 6.87, respectively[2]. Cell Viability Assay[1] Cell Line: |
| In Vivo | TP-024 (FTBMT) (30 mg/kg, 90 minutes) exhibits antipsychotic-like activity without causing catalepsy in mice[2].TP-024 (3 or 10 mg/kg, 48 hours) improves recognition and spatial working memory in rats[2].TP-024 (3, 10, 30 mg/kg, 2 hours) stimulates neuronal activity in brain regions related to cognition[2]. Animal Model: |
| Name | TP-024 |
| CAS | 1358575-02-6 |
| Formula | C19H16F4N4O |
| Molar Mass | 392.35 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Tokumaru K, et al. Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. Bioorg Med Chem. 2017 Jun 15;25(12):3098-3115. [2]. Nishiyama K, et al. FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia. J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. |